Trastuzumab: tested in a combination

382 studies: another drug in the study is under test too. Page 1 of 4. Open to participants first (81), then studies with results posted, then the rest; newest registration first within each.

• HER2-positive Breast Cancer Without Intravenous Neoadjuvant TherapyNot yet recruitingNCT07848633Phase 2Report a problem
• Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast CancerRecruitingNCT07635342Phase 2Report a problem
• A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast CancerNot yet recruitingNCT07601620Phase 1Report a problem
• Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast CancerNot yet recruitingNCT07589972Not applicableReport a problem
• Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisRecruitingNCT07578116Phase 3Report a problem
• Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)Not yet recruitingNCT07565324Phase 2Report a problem
• Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer or Urothelial Carcinoma After Failure of Standard TherapyRecruitingNCT07506057Phase 2Report a problem
• Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®Not yet recruitingNCT07495930Phase 1Report a problem
• Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialRecruitingNCT07407920Phase 2Report a problem
• Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast CancerRecruitingNCT07402473Phase 2Report a problem
• Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerRecruitingNCT07393425Phase 2Report a problem
• Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast CancerRecruitingNCT07340398Phase 2Report a problem
• Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric CancerRecruitingNCT07334431Phase 1/2Report a problem
• An Exploratory Study on Individualized Neoadjuvant Treatment Regimens for Early HR+/HER2+ Breast CancerNot yet recruitingNCT07300215Phase 2Report a problem
• An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast CancerNot yet recruitingNCT07299890Phase 2Report a problem
• A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.Not yet recruitingNCT07290166Phase 2Report a problem
• Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal MetastasisRecruitingNCT07263425Phase 2Report a problem
• Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerRecruitingNCT07193394Phase 2Report a problem
• Identification of HER2-Positive Breast Cancer Molecular Characterization and SubtypesNot yet recruitingNCT07187752Not applicableReport a problem
• Asciminib in HER2+ Breast Cancer Brain MetastasesRecruitingNCT07136428Phase 1/2Report a problem
• Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal CancerRecruitingNCT07108127Phase 2Report a problem
• Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerRecruitingNCT07095023Not applicableReport a problem
• Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal CancerNot yet recruitingNCT07059338Phase 2Report a problem
• SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain MetastasesNot yet recruitingNCT06975475Phase 2Report a problem
• This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.Not yet recruitingNCT06973525Phase 2Report a problem
• ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabRecruitingNCT06876714Phase 3Report a problem
• Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II StudyEnrolling by invitationNCT06843681Phase 2Report a problem
• Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)RecruitingNCT06832904Phase 2Report a problem
• Pyrotinib in HER2-positive Early Breast CancerNot yet recruitingNCT06718335Not applicableReport a problem
• Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ PatiensRecruitingNCT06572319Phase 1/2Report a problem
• The Sagittarius TrialRecruitingNCT06490536Phase 3Report a problem
• Pyrotinib and Subcutaneous Preparation of Trastuzumab Combined With Capecitabine Neoadjuvant Therapy for HER2+ Study of Breast CancerNot yet recruitingNCT06483386Phase 2Report a problem
• Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.RecruitingNCT06450314Phase 2Report a problem
• BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast CancerRecruitingNCT06441890Phase 2Report a problem
• The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2Report a problem
• Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJCNot yet recruitingNCT06439550Phase 2Report a problem
• Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryRecruitingNCT06348134Phase 2Report a problem
• Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast CancerRecruitingNCT06276868Phase 2Report a problem
• Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 StudyRecruitingNCT06162559Phase 1Report a problem
• A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric CancerRecruitingNCT06123338Phase 2Report a problem
• Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast CancerRecruitingNCT06035679Not applicableReport a problem
• Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingNCT06031233Phase 4Report a problem
• Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility StudyRecruitingNCT06016387Phase 2Report a problem
• A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast CancerRecruitingNCT06000917Phase 2Report a problem
• Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric CancerRecruitingNCT05975749Phase 2Report a problem
• Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast CancerRecruitingNCT05955170Phase 2Report a problem
• A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BCRecruitingNCT05945368Phase 2Report a problem
• Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast CancerRecruitingNCT05891561Phase 2Report a problem
• Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI ResearchRecruitingNCT05885776Phase 2Report a problem
• Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseRecruitingNCT05800275Phase 2Report a problem
• DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsRecruitingNCT05786716Phase 2/3Report a problem
• First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)RecruitingNCT05749900Phase 1/2Report a problem
• Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2Report a problem
• DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingNCT05722886Phase 2/3Report a problem
• A Study of Tucatinib and Trastuzumab in People With Rectal CancerRecruitingNCT05672524Phase 2Report a problem
• Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast CancerRecruitingNCT05659056Phase 2Report a problem
• Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line TherapyRecruitingNCT05640830Phase 1/2Report a problem
• Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast CancerRecruitingNCT05638594Phase 2Report a problem
• Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingNCT05615818Phase 3Report a problem
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2Report a problem
• Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)Not yet recruitingNCT05577923Phase 2Report a problem
• Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast CancerRecruitingNCT05530057Phase 2Report a problem
• Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)Not yet recruitingNCT05388500Phase 3Report a problem
• Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingNCT05332561Phase 2Report a problem
• A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerRecruitingNCT05253651Phase 3Report a problem
• Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBCRecruitingNCT05228951Phase 2Report a problem
• SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric AdenocarcinomaNot yet recruitingNCT05218148Phase 2Report a problem
• TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal CancerRecruitingNCT05188313Phase 3Report a problem
• The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2Report a problem
• Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HPNot yet recruitingNCT04929548Phase 4Report a problem
• Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)Not yet recruitingNCT04922008Phase 2Report a problem
• ATEMPT 2.0: Adjuvant T-DM1 vs THRecruitingNCT04893109Phase 2Report a problem
• Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersRecruitingNCT04886531Phase 2Report a problem
• Improving Public Cancer Care by Implementing Precision Medicine in NorwayRecruitingNCT04817956Phase 2Report a problem
• Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular DysfunctionRecruitingNCT04680442Phase 2Report a problem
• Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast CancerRecruitingNCT04481932Phase 2Report a problem
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2Report a problem
• Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast CancerNot yet recruitingNCT04158856Phase 2Report a problem
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2Report a problem
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2Report a problem
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2Report a problem
• Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)Active, not recruitingNCT06136897Phase 2Results postedReport a problem
• Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate CancerCompletedNCT05730712Phase 2Results postedReport a problem
• A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery SystemCompletedNCT05275010Phase 1Results postedReport a problem
• Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerActive, not recruitingNCT05113251Phase 3Results postedReport a problem
• A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedNCT04632992Phase 2Results postedReport a problem
• A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative ResectionTerminatedNCT04510285Phase 2Results postedReport a problem
• Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal AdenocarcinomasCompletedNCT03783936Phase 2Results postedReport a problem
• Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMDTerminatedNCT03501979Phase 2Results postedReport a problem
• Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast CancerCompletedNCT03425656Phase 3Results postedReport a problem
• S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by SurgeryCompletedNCT03365882Phase 2Results postedReport a problem
• Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast CancerActive, not recruitingNCT02827877Phase 2Results postedReport a problem
• Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.CompletedNCT02789657Phase 2Results postedReport a problem
• A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast CancerCompletedNCT02748213Phase 2Results postedReport a problem
• Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After SurgeryCompletedNCT02654119Phase 2Results postedReport a problem
• A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-RadiotherapyCompletedNCT02536339Phase 2Results postedReport a problem
• Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or BevacizumabActive, not recruitingNCT02436993Phase 2Results postedReport a problem
• Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment RegimenCompletedNCT02419742Phase 4Results postedReport a problem
• Neoadjuvant Hormonal Therapy Combined With ChemoimmunotherapyTerminatedNCT02345772Phase 1/2Results postedReport a problem
• Pembrolizumab and Monoclonal Antibody Therapy in Advanced CancerTerminatedNCT02318901Phase 1/2Results postedReport a problem

← Trastuzumab